Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Barrett Esophagus 4Stomach Neoplasms 2Pancreatic Neoplasms 2Colorectal Neoplasms 2Zollinger-Ellison Syndrome 1Stomach Ulcer 1Precancerous Gastric Lesions 1Peripheral Nervous System Diseases 1Inflammation 1Esophagitis, Peptic 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasia 1Atrophy 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Omeprazole × Gastrointestinal × Clear all
NCT04930991 2026-06-01

OU202005AJ

University of Oklahoma

Phase EARLY_PHASE1 Terminated
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05680870 2025-09-09

The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients

Tanta University

Phase 3 Completed
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Peripheral Nervous System Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡